ClinicalTrials.gg
Sign In
RecruitingNCT07672925FLowMDUpdated Jun 29, 2026

FlowMD Feasibility Study

An interventional study of Intervention in Anxiety, sponsored by National University of Natural Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by National University of Natural Medicine · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2025, registered Jun 2026).
  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the FlowMD mobile app is feasible to be used to manage mild anxiety in adults. It will also learn if the app is effective at managing anxiety in adults.

Participants will:

Use the FlowMD app daily to complete a 1-5 minute guided breathwork session over the course of 4 weeks.

Complete surveys at the beginning, midpoint, and end of the study to measure anxiety levels and usability of the app.

02

Conditions studied

  • Anxiety

Browse trials for

Keywords

  • anxiety
  • breathwork
  • meditation
  • feasibility
  • mobile app
03

In context

Anxiety Disorders

7,201 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's planned enrollment of 40 is below the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

National University of Natural Medicine is the lead sponsor of 39 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18-65 years old
  • Have an anxiety disorder
  • Have a smartphone
  • Able to download the FlowMD app
  • Willing to use the FlowMD meditation app for a daily 1-5 minute session for four consecutive weeks
  • Able to provide feedback on the experience using the app
  • Willing to participate in surveys to measure changes in anxiety levels

Exclusion criteria

Exclusion Criteria:

  • Are undergoing significant changes in psychiatric medication or therapy
  • Have severe psychiatric conditions that might interfere with study participation (Schizophrenia, Bipolar Disorder, Major Depressive Disorder)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Daily guided breathwork using the FlowMD mobile app

    Other: Intervention

  • No intervention
    Control

    Control Group with no Intervention

Interventions

  • OtherIntervention

    4 weeks daily usage of FlowMD guided breathwork sessions

06

What researchers measure

Primary outcomes

  1. Feasibility of the FlowMD mobile app

    Outcome measured using the Feasibility Survey with a Max Score of 32 indicating strong feasibility

    Time frame: From enrollment to end of intervention at 4 weeks

Secondary outcomes

  1. Generalized Anxiety Disorder-7 (GAD-7) Score

    Outcome measured using the Generalized Anxiety Disorder-7 (GAD-7) survey. Score scale 0-21. Lower score indicates condition improvement.

    Time frame: From Enrollment to the end of the intervention at 4 weeks

  2. Hamilton Anxiety Rating Scale (HAM-A) Score

    Outcome measured using the Hamilton Anxiety Rating Scale (HAM-A) survey. Score scale 0-56. Lower score indicates condition improvement.

    Time frame: From Enrollment to the end of the intervention at 4 weeks

  3. State-Trait Anxiety Inventory (STAI)

    Outcome measured using the State-Trait Anxiety Inventory (STAI) survey. Score scale 20-80. Lower score indicates condition improvement.

    Time frame: From Enrollment to the end of the intervention at 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 3,836 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 14 months is above that.

Counting every sponsor, half of 3,938 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 29, 2026
StartActual
Oct 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07672925
Lead sponsor
National University of Natural Medicine
Responsible party
Heather Zwickey (Principal Investigator, National University of Natural Medicine) — Principal investigator
First posted
Jun 29, 2026
Start date
Oct 15, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Michelle T Berg, Master of Clinical Research
Contact
FlowMDFeasibility@nunm.edu
1 503 552 1885
Heather Zwickey, PhD
principal investigator · National University of Natural Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Anxiety Disorders →

Other studies from this sponsor

National University of Natural Medicine

Start the discussion